{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:23:27Z","timestamp":1787239407907,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1378\/chest.128.4.2765","type":"journal-article","created":{"date-parts":[[2005,10,19]],"date-time":"2005-10-19T13:57:43Z","timestamp":1129730263000},"page":"2765-2771","source":"Crossref","is-referenced-by-count":24,"title":["Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis"],"prefix":"10.1016","volume":"128","author":[{"given":"Dario","family":"Prais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Danino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Schonfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.128.4.2765_bib1","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","article-title":"Respiratory syncytial virus and parainfluenza virus","volume":"344","author":"Hall","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.128.4.2765_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1542\/pir.9-6-191","article-title":"McIntosh, EDG Respiratory syncytial virus infections in infants and children: diagnosis and treatment","volume":"9","year":"1987","journal-title":"Pediatr Rev"},{"key":"10.1378\/chest.128.4.2765_bib3","first-page":"199","article-title":"Respiratory syncytial virus infection in children with bronchopulmonary dysplasia","volume":"82","author":"Groothuis","year":"1988","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib4","first-page":"527","article-title":"Rehospitalization for respiratory illness in infants less than 32 weeks' gestation","volume":"88","author":"Cunningham","year":"1991","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib5","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJM199311183292102","article-title":"Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children","volume":"329","author":"Groothuis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.128.4.2765_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1542\/peds.99.1.93","article-title":"The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis","volume":"99","year":"1997","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1542\/peds.102.5.1211","article-title":"American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib9","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1542\/peds.112.6.1442","volume":"112","year":"2003","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1542\/peds.112.3.548","article-title":"Admissions to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use","volume":"112","author":"Prais","year":"2003","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/01.inf.0000069765.43405.3b","article-title":"Risk factors for bronchiolitis-associated deaths among infants in the United States","volume":"22","author":"Holman","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1378\/chest.128.4.2765_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/JCM.23.3.485-488.1986","article-title":"Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by a commercial enzyme immunoassay","volume":"23","author":"Swenson","year":"1986","journal-title":"J Clin Microbiol"},{"key":"10.1378\/chest.128.4.2765_bib14","article-title":"Israel Disease Control Center","year":"2002","journal-title":"Very low birth weight children in Israel: annual National Report"},{"key":"10.1378\/chest.128.4.2765_bib15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/archpedi.156.10.1034","article-title":"Economic analysis of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review","volume":"156","author":"Kamal-Bahl","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1378\/chest.128.4.2765_bib16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0149-2918(00)83032-5","article-title":"Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis","volume":"22","author":"Lofland","year":"2000","journal-title":"Clin Ther"},{"key":"10.1378\/chest.128.4.2765_bib17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0149-2918(00)88326-5","article-title":"Impact of palivizumab on expected cost of respiratory syncytial virus infection in preterm infants: potential for savings","volume":"21","author":"Marchetti","year":"1999","journal-title":"Clin Ther"},{"key":"10.1378\/chest.128.4.2765_bib18","first-page":"55","article-title":"Respiratory syncytial virus and premature infants born at 32 weeks' gestation or early","volume":"154","author":"Stevens","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1378\/chest.128.4.2765_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/adc.83.4.313","article-title":"Respiratory syncytial virus infection in high-risk infants and the potential of prophylaxis in a United Kingdom cohort","volume":"83","author":"Clark","year":"2000","journal-title":"Arch Dis Child"},{"key":"10.1378\/chest.128.4.2765_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ppul.1084","article-title":"Respiratory syncytial virus immune globulin: decision and costs","volume":"32","author":"Barton","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1378\/chest.128.4.2765_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archpedi.156.12.1251","article-title":"Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk children","volume":"156","author":"Shireman","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1378\/chest.128.4.2765_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1046\/j.1440-1754.2000.00303.x","article-title":"Outcome of respiratory syncytial virus infection and cost-benefit analysis of prophylaxis","volume":"36","author":"Numa","year":"2000","journal-title":"J Paediatr Child Health"},{"key":"10.1378\/chest.128.4.2765_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1542\/peds.104.3.419","article-title":"Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants","volume":"104","author":"Joffe","year":"1999","journal-title":"Pediatrics"},{"key":"10.1378\/chest.128.4.2765_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00431-002-1106-6","article-title":"Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany","volume":"162","author":"Roeckl-Wiedmann","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1378\/chest.128.4.2765_bib25","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215527013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215527013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T06:54:01Z","timestamp":1586501641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215527013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0012369215527013"],"URL":"https:\/\/doi.org\/10.1378\/chest.128.4.2765","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.10154.467644","asserted-by":"object"}]},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}